Scharf, C.; Paal, M.; Schroeder, I.; Vogeser, M.; Draenert, R.; Irlbeck, M.; Zoller, M.; Liebchen, U.
Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice. Antibiotics 2020, 9, 131.
https://doi.org/10.3390/antibiotics9030131
AMA Style
Scharf C, Paal M, Schroeder I, Vogeser M, Draenert R, Irlbeck M, Zoller M, Liebchen U.
Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice. Antibiotics. 2020; 9(3):131.
https://doi.org/10.3390/antibiotics9030131
Chicago/Turabian Style
Scharf, Christina, Michael Paal, Ines Schroeder, Michael Vogeser, Rika Draenert, Michael Irlbeck, Michael Zoller, and Uwe Liebchen.
2020. "Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice" Antibiotics 9, no. 3: 131.
https://doi.org/10.3390/antibiotics9030131
APA Style
Scharf, C., Paal, M., Schroeder, I., Vogeser, M., Draenert, R., Irlbeck, M., Zoller, M., & Liebchen, U.
(2020). Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice. Antibiotics, 9(3), 131.
https://doi.org/10.3390/antibiotics9030131
